Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013

Blood (2024) 144 (Supplement 1): 961.

https://doi.org/10.1182/blood-2024-199060

Published: 2024

Journal Articles

Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia - Data from the GMALL Study Group

Anjali Cremer, Maher Hanoun, Ralph Wäsch, Simon Raffel, Klaus Wethmar, Andreas Viardot, Walter Fiedler, Knut Wendelin, Lore Marretta, Wolfram Jung, Roland Schroers, Vladan Vucinic, Monika Brüggemann, Stefan Schwartz, Hubert Serve, Nicola Goekbuget

Blood (2024) 144 (Supplement 1): 1436.

https://doi.org/10.1182/blood-2024-202270

Published: 2024

Journal Articles

Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group

Blood (2024) 144 (Supplement 1): 3554.

https://doi.org/10.1182/blood-2024-204560

Published: 2024

Journal Articles

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Blood (2023) 142 (Supplement 1): 828.

https://doi.org/10.1182/blood-2023-179442

Published: 2023

Journal Articles

Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

Blood (2022) 140 (Supplement 1): 115–117.

https://doi.org/10.1182/blood-2022-158381

Published: 2022

Journal Articles

Immediate Allogeneic Hematopietic Stem Cell Transplantation for Patients with NPM1-Mutated AML in Molecular Relapse

Kerstin Schaefer-Eckart, Knut Wendelin, Sabine Dressler, Johannes Gärtner, Lisa Schneider, Christian Thiede

Blood (2021) 138 (Supplement 1): 2288.

https://doi.org/10.1182/blood-2021-146549

Published: 2021

Journal Articles

Gemtuzumab Ozogamicin Plus Midostaurin in Combination with Standard Intensive Induction Therapy in Newly Diagnosed AML: Results from a Phase-I Study

Christoph Röllig, Christoph Schliemann, Jan-Henrik Mikesch, Lars Fransecky, Claudia D. Baldus, Björn-Niklas Heydrich, Maher Hanoun, Richard Noppeney, Sebastian Scholl, Ulf Schnetzke, Kerstin Schäfer-Eckart, Knut Wendelin, Martin Wermke, Manja Reimann, Frank Fiebig, Theresa Kretschmann, Friedrich Stoelzel, Nael Alakel, Martin Bornhäuser

Blood (2021) 138 (Supplement 1): 2324.

https://doi.org/10.1182/blood-2021-150069

Published: 2021

Journal Articles

First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL)

Blood (2021) 138 (Supplement 1): 362.

https://doi.org/10.1182/blood-2021-146306

Published: 2021

Journal Articles

Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-137350

Published: 2020

Journal Articles

Nilotinib (Tasigna ® ) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1- Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)

Blood (2018) 132 (Supplement 1): 31.

https://doi.org/10.1182/blood-2018-99-114552

Published: 2018

Journal Articles

Evaluation of Minimal Residual Disease (MRD) and MRD-Based Treatment Decisions in Ph/BCR-ABL Negative Adult Acute Lymphoblastic Leukemia (ALL): Experience from the German Multicenter Study Group for Adult ALL (GMALL)

Nicola Goekbuget, MD, Monika Brüggemann, Joachim Beck, MD, Christoph Faul, MD, Christian Koenecke, MD, Heinz A. Horst, MD PhD, Mustafa Kondakci, MD, Doris M. Kraemer, MD, PhD, Christoph Lutz, MD, Bernd Spriewald, MD, Michael Starck, MD, Christoph Rollig, MD MSC, Matthias Stelljes, MD, Andreas Viardot, MD, Ralph Wäsch, Knut Wendelin, MD, Hubert Serve, Michael Kneba, MD, Dieter Hoelzer, MD PhD

Blood (2017) 130 (Supplement 1): 139.

https://doi.org/10.1182/blood.V130.Suppl_1.139.139

Published: 2017

Journal Articles

Early Allogeneic Blood Stem Cell Transplantation after Melphalan-Induced Aplasia for Patients with Primary Refractory or Relapsed Acute Myeloid Leukemia - Results of a Retrospective Single Center Analysis

Kerstin Schaefer-Eckart, MD, Knut Wendelin, MD, Sabine Dressler, MD, Starke Martina, MD, Martin Wilhelm, MD PhD

Blood (2016) 128 (22): 5839.

https://doi.org/10.1182/blood.V128.22.5839.5839

Published: 2016

Journal Articles

Consolidation Therapy Is Associated with Significantly Lower Bleeding Risk Compared to Induction Therapy in Patients with Acute Myeloid Leukemia

Kerstin Schaefer-Eckart, MD, Knut Wendelin, MD, Bettina Pilz, Michael Kramer, PhD, Gerhard Ehninger, MD, Martin Wilhelm, MD PhD, Hannes Wandt, MD

Blood (2014) 124 (21): 3686.

https://doi.org/10.1182/blood.V124.21.3686.3686

Published: 2014

Journal Articles

Significant Improvement Of Outcome In Adolescents and Young adults (AYAs) Aged 15-35 Years With Acute Lymphoblastic Leukemia (ALL) With a Pediatric Derived Adult ALL Protocol; Results Of 1529 AYAs In 2 Consecutive Trials Of The German Multicenter Study Group For Adult ALL (GMALL)

Blood (2013) 122 (21): 839.

https://doi.org/10.1182/blood.V122.21.839.839

Published: 2013

Journal Articles

Moderate Intensive Chemotherapy Including CNS-Prophylaxis with Liposomal Cytarabine Is Feasible and effective in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Trial From the German Multicenter Study Group for Adult ALL (GMALL)

Nicola Goekbuget, MD, Joachim Beck, MD, Monika Brueggemann, Thomas Burmeister, MD, Eike C. Buss, MD, Norbert Frickhofen, MD, Andreas Huettmann, MD, Anke Morgner, MD, Albrecht Reichle, Ingo Schmidt-Wolf, MD, Stefan Schwartz, MD, Hubert Serve, Prof. Dr. med., Bernd M Spriewald, MD, Michael Starck, MD, Matthias Stelljes, MD, Andreas Viardot, MD, Knut Wendelin, MD, Dieter Hoelzer, MD

Blood (2012) 120 (21): 1493.

https://doi.org/10.1182/blood.V120.21.1493.1493

Published: 2012

Journal Articles

Long Term Follow-up of 121 Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Treated in Prospective GMALL Trials Supports a Greater Emphasis On Allogeneic SCT as Definitive Postremission Therapy.

Blood (2012) 120 (21): 2608.

https://doi.org/10.1182/blood.V120.21.2608.2608

Published: 2012

Journal Articles

Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation

Blood (2012) 120 (10): 2032–2041.

https://doi.org/10.1182/blood-2011-12-399287

Published: 2012

Includes: Supplemental data

Journal Articles

Successful Subtype Oriented Treatment Strategies in Adult T-All; Results of 744 Patients Treated in Three Consecutive GMALL Studies.

Blood (2009) 114 (22): 324.

https://doi.org/10.1182/blood.V114.22.324.324

Published: 2009

Journal Articles

A Therapeutic Platelet Transfusion Strategy without Routine Prophylactic Transfusion Is Feasible and Safe and Reduces Platelet Transfusion Numbers Significantly: Preliminary Analysis of a Randomized Study in Patients after High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation

Hannes Wandt, MD, Knut Wendelin, MD, Kerstin Schaefer-Eckart, MD, Markus Thalheimer, MD, Mario Stephan Schubert, MD, Roland Conradi, MD, Rainer Schwerdtfeger, MD, Lothar Leimer, MD, Martin Kaufmann, MD, Gottfried Dölken, MD, Anne Friederike Klenner, MD, Markus Schaich, MD, Gerhard Ehninger, MD

Blood (2008) 112 (11): 286.

https://doi.org/10.1182/blood.V112.11.286.286

Published: 2008

Journal Articles

Interim Analysis of a Prospective Randomised Study Comparing a Therapeutic Platelet Transfusion Strategy with the Prophylactic Platelet Transfusion Standard in Patients after Autologous Peripheral Stem Cell Transplantation (ASCT).

Kerstin Schaefer-Eckart, MD, Knut Wendelin, MD, Martin Wilhelm, MD, PhD, U. Mahlknecht, MD, R. Conradi, MD, M. Schaich, MD, L. Leimer, MD, Hannes Wandt, MD

Blood (2006) 108 (11): 577.

https://doi.org/10.1182/blood.V108.11.577.577

Published: 2006

NARROW

Chemotherapy or Stem Cell Transplantation in Adult High Risk Ph/BCR::ABL1-Negative ALL Patients with Early MRD Negativity: Results of the Randomized GMALL Trial 08/2013

Outcome of Patients with Hematologic or Molecular Relapsed/Refractory (R/R) Acute T- Lymphoblastic Leukemia - Data from the GMALL Study Group

Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group

CNS Irradiation in Adult De Novo B-Precursor ALL / Lbl: Results of the Randomized GMALL T rial 08/2013 Indicate Potential Antileukemic Efficacy

Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

Immediate Allogeneic Hematopietic Stem Cell Transplantation for Patients with NPM1-Mutated AML in Molecular Relapse

Gemtuzumab Ozogamicin Plus Midostaurin in Combination with Standard Intensive Induction Therapy in Newly Diagnosed AML: Results from a Phase-I Study

First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL)

Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)

Nilotinib (Tasigna ® ) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1- Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)

Evaluation of Minimal Residual Disease (MRD) and MRD-Based Treatment Decisions in Ph/BCR-ABL Negative Adult Acute Lymphoblastic Leukemia (ALL): Experience from the German Multicenter Study Group for Adult ALL (GMALL)

Early Allogeneic Blood Stem Cell Transplantation after Melphalan-Induced Aplasia for Patients with Primary Refractory or Relapsed Acute Myeloid Leukemia - Results of a Retrospective Single Center Analysis

Consolidation Therapy Is Associated with Significantly Lower Bleeding Risk Compared to Induction Therapy in Patients with Acute Myeloid Leukemia

Significant Improvement Of Outcome In Adolescents and Young adults (AYAs) Aged 15-35 Years With Acute Lymphoblastic Leukemia (ALL) With a Pediatric Derived Adult ALL Protocol; Results Of 1529 AYAs In 2 Consecutive Trials Of The German Multicenter Study Group For Adult ALL (GMALL)

Moderate Intensive Chemotherapy Including CNS-Prophylaxis with Liposomal Cytarabine Is Feasible and effective in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Trial From the German Multicenter Study Group for Adult ALL (GMALL)

Long Term Follow-up of 121 Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Treated in Prospective GMALL Trials Supports a Greater Emphasis On Allogeneic SCT as Definitive Postremission Therapy.

Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation

Successful Subtype Oriented Treatment Strategies in Adult T-All; Results of 744 Patients Treated in Three Consecutive GMALL Studies.

Interim Analysis of a Prospective Randomised Study Comparing a Therapeutic Platelet Transfusion Strategy with the Prophylactic Platelet Transfusion Standard in Patients after Autologous Peripheral Stem Cell Transplantation (ASCT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only